Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices

The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting

(2015) Nicholas J. Di Bella et al.   Clinical Lymphoma Myeloma & Leukemia

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

(2015) N C P Cross et al.   LEUKEMIA

Bosutinibversusimatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

(2014) Tim H. Brümmendorf et al.   BRITISH JOURNAL OF HAEMATOLOGY

Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase

(2014) Annie Guérin et al.   CURRENT MEDICAL RESEARCH AND OPINION

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

(2013) Lorenzo Falchi et al.   AMERICAN JOURNAL OF HEMATOLOGY

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

(2013) T. P. Hughes et al.   BLOOD

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

(2013) E. Jabbour et al.   BLOOD

Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?

(2013) F.-X. Mahon et al.   CLINICAL CANCER RESEARCH

Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale

(2013) H. E. White et al.   CLINICAL CHEMISTRY

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

(2013) Stuart L. Goldberg et al.   CURRENT MEDICAL RESEARCH AND OPINION

Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting

(2013) Mansoor N. Saleh et al.   CURRENT MEDICAL RESEARCH AND OPINION

BCR–ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring

(2013) Martin H Luu et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

(2013) G. Etienne et al.   HAEMATOLOGICA

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

(2013) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

(2013) Richard D. Press et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Molecular Monitoring of Chronic Myeloid Leukemia

(2013) ChaoJie Zhen et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia

(2013) Annie Guérin et al.   JOURNAL OF MEDICAL ECONOMICS

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

(2012) H. Kantarjian et al.   BLOOD

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

(2012) B Hanfstein et al.   LEUKEMIA

Standardized definitions of molecular response in chronic myeloid leukemia

(2012) N C P Cross et al.   LEUKEMIA

Design and Analytic Validation of BCR-ABL1 Quantitative Reverse Transcription Polymerase Chain Reaction Assay for Monitoring Minimal Residual Disease

(2011) Lawrence J Jennings et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Translating Trial-Based Molecular Monitoring Into Clinical Practice: Importance of International Standards and Practical Considerations for Community Practitioners

(2011) Luke P. Akard et al.   Clinical Lymphoma Myeloma & Leukemia

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

(2011) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

(2010) T. P. Hughes et al.   BLOOD

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

(2010) H. E. White et al.   BLOOD

Standardisation of molecular monitoring for chronic myeloid leukaemia

(2009) Nicholas C.P. Cross   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

How I monitor residual disease in chronic myeloid leukemia

(2009) J. P. Radich   BLOOD

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

(2009) A. Quintas-Cardama et al.   BLOOD

Harmonization of molecular monitoring of CML therapy in Europe

(2009) M C Müller et al.   LEUKEMIA

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

(2008) S. Branford et al.   BLOOD